Clinical Trials Logo

PPHN clinical trials

View clinical trials related to PPHN.

Filter by:
  • None
  • Page 1

NCT ID: NCT06043635 Withdrawn - Clinical trials for Hypoxic Respiratory Failure

Predictors of Inhaled Nitric Oxide Responsiveness in Patients With PPHN

PINOR
Start date: July 15, 2021
Phase:
Study type: Observational

To identify biochemical, clinical, or genetic biomarkers that may predict responsiveness to iNO in neonates with PPHN/HRF. The primary outcome will be identification of any biomarker(s) associated with response to iNO therapy. We will evaluate related biomarkers at various time-points during disease progression and in response to therapy, including single nucleotide polymorphisms in the cyclic adenosine monophosphate/cyclic guanosine monophosphate-Phosphodiesterase (PDE) pathway, indicators of metabolic dysregulation and inflammation, as well as biochemical markers of heart strain. We will perform targeted neonatal echocardiograms to evaluate severity of PPHN and heart function both as an added clinical biomarker and to follow disease progression.

NCT ID: NCT05527704 Recruiting - Respiratory Failure Clinical Trials

the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

REFSAL
Start date: December 31, 2021
Phase: Phase 3
Study type: Interventional

Clinical trial evaluating the efficacy and safety of salbutamol for the treatment of neonates with a gestational age between 32 and 42 weeks with transient tachypnoea of the newborn (TTN).

NCT ID: NCT04328636 Completed - Clinical trials for Persistent Pulmonary Hypertension of the Newborn

Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn

NebMag
Start date: November 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this pilot randomized controlled blinded study is to evaluate the feasibility of using nebulized magnesium sulfate in the treatment of PPHN.

NCT ID: NCT03499418 Withdrawn - Clinical trials for Transient Tachypnea of the Newborn

Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates

PRE-HIFREQ
Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

Transient Tachypnea of the Newborn (TTN) is one of the common causes of neonatal respiratory distress as a result of delayed clearance of fetal lung fluid. Neonates with TTN usually require noninvasive respiratory support (e.g. nasal cannula, nasal CPAP) and may need supplemental oxygen therapy to maintain normal oxygen saturation levels. There have also been reports of "malignant TTN," in which affected children develop persistent pulmonary hypertension of the newborn (PPHN).

NCT ID: NCT01069861 Terminated - Clinical trials for Hypoxic Respiratory Failure

Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

Sildenafil is efficacious in newborns with persistent pulmonary hypertension and its use will reduce the need for inhaled nitric oxide.